Table 4.
Procedural parameters among patients receiving three different initial bolus heparin dosages for each non-vitamin K antagonist oral anticoagulant
| Dabigatran | P value | Rivaroxaban | P value | Apixaban | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heparin dosage: | 110 U/kg | 120 U/kg | 130 U/kg | 110 U/kg | 120 U/kg | 130 U/kg | 110 U/kg | 120 U/kg | 130 U/kg | |||
| Number of patients | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | |||
| Procedural variables | ||||||||||||
| Presenting rhythm | ||||||||||||
| Sinus rhythm | 17 (57 %) | 16 (53 %) | 18 (60 %) | 0.87 | 17 (57 %) | 17 (57 %) | 18 (60 %) | 0.99 | 19 (63 %) | 20 (67 %) | 17 (57 %) | 0.72 |
| AF/AFL | 13 (43 %) | 14 (47 %) | 12 (40 %) | 13 (43 %) | 13 (43 %) | 12 (40 %) | 11 (37 %) | 10 (33 %) | 13 (43 %) | |||
| Acute success | 97 % (29/30) | 97 % (29/30) | 100 % (30/30) | 0.94 | 97 % (29/30) | 100 % (30/30) | 97 % (29/630) | 0.94 | 100 % (30/30) | 97 % (29/30) | 100 % (30/30) | 0.88 |
| Procedure time (min) | 102 ± 22 | 112 ± 26 | 105 ± 22 | 0.47 | 107 ± 13 | 103 ± 22 | 105 ± 18 | 0.83 | 103 ± 19 | 105 ± 19 | 107 ± 21 | 0.59 |
| Fluoroscopy time (min) | 30 ± 7 | 36 ± 13 | 33 ± 10 | 0.23 | 33 ± 7 | 33 ± 5 | 33 ± 5 | 0.91 | 32 ± 7 | 32 ± 6 | 34 ± 11 | 0.76 |
| RF time (min) | 33 ± 9 | 33 ± 9 | 33 ± 7 | 0.88 | 32 ± 5 | 34 ± 5 | 33 ± 6 | 0.30 | 33 ± 4 | 32 ± 5 | 34 ± 6 | 0.12 |
| Intraprocedural cardioversion | 9 (30 %) | 10 (33 %) | 7 (23 %) | 0.69 | 10 (33 %) | 11 (37 %) | 8 (27 %) | 0.70 | 9 (30 %) | 8 (27 %) | 11 (37 %) | 0.70 |
| PVAI success | 100 % (30/30) | 100 % (30/30) | 100 % (30/30) | 1 | 100 % (30/30) | 100 % (30/30) | 100 % (30/30) | 1 | 100 % (30/30) | 100 % (30/30) | 100 % (30/30) | 1 |
Values are presented as mean ± standard deviation
AF atrial fibrillation, AFL atrial flutter, PVAI pulmonary vein atrium isolation, RF radiofrequency